Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Pharming Group NV Leiden (PK) PHGUF

Healthcare Biotechnology
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema... see more

Recent & Breaking News (PINL:PHGUF)

    Pharming announces first patient enrolled in pediatric clinical trial of leniolisib

    Canada NewsWire February 21, 2023

    Pharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under Accelerated Assessment for leniolisib

    PR Newswire October 28, 2022

    Pharming announces the publication of data from a compassionate use programme of RUCONEST® in COVID-19 patients in a peer-reviewed journal

    PR Newswire August 17, 2020

    Pharming Group reports financial results for the first half of 2020

    PR Newswire July 30, 2020

    Pharming Reports on Annual General Meeting of Shareholders

    PR Newswire May 20, 2020

    Pharming Celebrates "hae day :-)"

    PR Newswire May 16, 2020

    Pharming Group Reports Financial Results for the First Quarter of 2020

    PR Newswire May 14, 2020

    Pharming Enters the Euronext Amsterdam Midkap-index (AMX)

    PR Newswire March 23, 2020

    Pharming Receives FDA Approval of New Facility for Expansion of RUCONEST® Production

    PR Newswire March 9, 2020

    Pharming Group Reports Strong Financial Results for the First Half of 2019

    PR Newswire July 26, 2019

    Pharming and Santarus announce poster presentation of pivotal clinical data for RUCONEST(R) (recombinant human C1 esterase inhibitor)

    Marketwired June 25, 2013

    Santarus and Pharming announce FDA acceptance for review of RUCONEST (recombinant human C1 esterase inhibitor) Biologics License Application

    Marketwired June 18, 2013

      Podcasts